en داخلی داخلی پژوهشی اصیل Original Article <span style="font-size:11pt"><span style="line-height:16.0pt"><span sans-serif="" style="font-family:Calibri,"><b><span new="" roman="" style="font-family:" times=""><span style="color:#660066">Background and Objective:</span></span></b><b> </b><span lang="EN" style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Determination of best preventive approach for gastrointestinal bleeding in Acute Coronary Syndrome (ACS) patients with high risk of gastrointestinal bleeding is crucial. This study aimed to determine the effect of pantoprazole on prevention of gastrointestinal bleeding in ACS patients with high risk of gastrointestinal bleeding</span></span><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:16.0pt"><span sans-serif="" style="font-family:Calibri,"><b><span new="" roman="" style="font-family:" times=""><span style="color:#660066">Methods: </span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">This randomized clinical trial was performed in emergency department of Imam Hussein Hospital in Tehran, Iran between 2018 and 2019 among 1276 consecutive ACS patients with high risk of gastrointestinal bleeding.The participants were randomly received either pantoprazole 40 mg or famotidine 40 mg daily. The melena, hematemesis, hematochezia, and hemoglobin level were compared across the groups after one month.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:16.0pt"><span sans-serif="" style="font-family:Calibri,"><b><span new="" roman="" style="font-family:" times=""><span style="color:#660066">Findings: </span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">The results in this study demonstrated that melena was seen in 1.1% and 3.8% in pantoprazole and famotidine groups, respectively with significant difference (P=0.002). Hematemesis was seen in 0.6% and 1.9% in pantoprazole and famotidine groups, respectively with significant difference (P=0.044). Also, hematochezia was seen in 0.3% and 0.8% in pantoprazole and famotidine groups, respectively without significant difference (P=0.452). The mean hemoglobin was 11.98 and 11.82 in pantoprazole and famotidine groups, respectively with significant difference (P=0.021). </span></span></span></span></span><br> <b><span style="font-size:11.0pt"><span style="line-height:107%"><span new="" roman="" style="font-family:" times=""><span style="color:#660066">Conclusion: </span></span></span></span></b><span style="font-size:10.0pt"><span style="line-height:107%"><span new="" roman="" style="font-family:" times="">This study showed that pantoprazole (versus famotidine) is effective for prevention of gastrointestinal bleeding in Acute Coronary Syndrome patients with high risk of gastrointestinal bleeding</span></span></span><span style="font-size:9.0pt"><span style="line-height:107%"><span new="" roman="" style="font-family:" times="">.</span></span></span> Pantoprazole, Gastrointestinal bleeding, Acute coronary syndrome 58 63 http://crms.mubabol.ac.ir/browse.php?a_code=A-10-165-1&slc_lang=en&sid=1 P Mohammadi Dr.mohammadiparisa@gmail.com 10031947532846001736 10031947532846001736 No Department of Internal Medicine, School of Medicine, shahid Beheshti University of Medical Sciences, Tehran, Iran M Sedaghat Sedaghat@sbmu.ac.ir 10031947532846001737 10031947532846001737 Yes Department of Internal Medicine, School of Medicine, shahid Beheshti University of Medical Sciences, Tehran, Iran Z Rashvandi Mahsa.rashvandi@yahoo.com 10031947532846001738 10031947532846001738 No Department of Internal Medicine, School of Medicine, shahid Beheshti University of Medical Sciences, Tehran, Iran